These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21099417)

  • 41. Safety and Efficacy Clinical Trials for SYL1001, a Novel Short Interfering RNA for the Treatment of Dry Eye Disease.
    Benitez-Del-Castillo JM; Moreno-Montañés J; Jiménez-Alfaro I; Muñoz-Negrete FJ; Turman K; Palumaa K; Sádaba B; González MV; Ruz V; Vargas B; Pañeda C; Martínez T; Bleau AM; Jimenez AI
    Invest Ophthalmol Vis Sci; 2016 Nov; 57(14):6447-6454. PubMed ID: 27893109
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride.
    Xiong C; Chen D; Liu J; Liu B; Li N; Zhou Y; Liang X; Ma P; Ye C; Ge J; Wang Z
    Invest Ophthalmol Vis Sci; 2008 May; 49(5):1850-6. PubMed ID: 18436819
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the efficacy of two lipid emulsion eyedrops in increasing tear film lipid layer thickness.
    Scaffidi RC; Korb DR
    Eye Contact Lens; 2007 Jan; 33(1):38-44. PubMed ID: 17224677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
    Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
    Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of hormone therapy for treating dry eye syndrome in postmenopausal women: a randomized trial.
    Piwkumsribonruang N; Somboonporn W; Luanratanakorn P; Kaewrudee S; Tharnprisan P; Soontrapa S
    J Med Assoc Thai; 2010 Jun; 93(6):647-52. PubMed ID: 20572368
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of a new lipid tear substitute in a mouse model of dry eye.
    Scifo C; Barabino S; De Pasquale G; Blanco AR; Mazzone MG; Rolando M
    Cornea; 2010 Jul; 29(7):802-6. PubMed ID: 20489574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Management of evaporative dry eye in ectrodactyly-ectodermal dysplasia-clefting syndrome.
    Ota Y; Matsumoto Y; Dogru M; Goto E; Uchino Y; Endo K; Tsubota K
    Optom Vis Sci; 2008 Sep; 85(9):E795-801. PubMed ID: 18772710
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model.
    Fujihara T; Murakami T; Fujita H; Nakamura M; Nakata K
    Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):96-100. PubMed ID: 11133853
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Corneal epithelial permeability and dry eye treatment.
    Benitez-del-Castillo JM; Aranguez C; Garcia-Sanchez J
    Adv Exp Med Biol; 2002; 506(Pt A):703-6. PubMed ID: 12613980
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye.
    Christensen MT; Cohen S; Rinehart J; Akers F; Pemberton B; Bloomenstein M; Lesher M; Kaplan D; Meadows D; Meuse P; Hearn C; Stein JM
    Curr Eye Res; 2004 Jan; 28(1):55-62. PubMed ID: 14704914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Irritation associated with tear-replacement ophthalmic drops. A pharmaceutical and subjective investigation.
    Fassihi AR; Naidoo NT
    S Afr Med J; 1989 Mar; 75(5):233-5. PubMed ID: 2648609
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Visual effect and residence time of artificial tears in dry eye subjects.
    Hall JQ; Ridder WH; Nguyen AL; Paugh JR
    Optom Vis Sci; 2011 Jul; 88(7):872-80. PubMed ID: 21532516
    [TBL] [Abstract][Full Text] [Related]  

  • 53. On call. I have recently noticed that my eyes are frequently dry. I have used saline eye drops, but they don't seem to help much. Is this normal?
    Kormos W
    Harv Mens Health Watch; 2012 Dec; 17(5):2. PubMed ID: 23373109
    [No Abstract]   [Full Text] [Related]  

  • 54. Efficacy of sodium hyaluronate eye drops of different osmolarities in the symptomatic treatment of dry eye patients.
    Milazzo G; Papa V; Aragona P; Russo S; Russo P; Di Bella A
    Adv Exp Med Biol; 2002; 506(Pt B):1233-5. PubMed ID: 12614058
    [No Abstract]   [Full Text] [Related]  

  • 55. Cyclosporine 0.09% solution (Cequa) for dry eye Disease.
    Med Lett Drugs Ther; 2019 Jul; 61(1577):116-118. PubMed ID: 31381551
    [No Abstract]   [Full Text] [Related]  

  • 56. Ocular safety of INS365 ophthalmic solution, a P2Y2 agonist, in patients with mild to moderate dry eye disease.
    Yerxa BR; Mundasad M; Sylvester RN; Garden JC; Cooper M; Kellerman DJ
    Adv Exp Med Biol; 2002; 506(Pt B):1251-7. PubMed ID: 12614062
    [No Abstract]   [Full Text] [Related]  

  • 57. Comments of the editor in chief.
    Liesegang TJ
    Am J Ophthalmol; 2014 Apr; 157(4):916-7. PubMed ID: 24630208
    [No Abstract]   [Full Text] [Related]  

  • 58. Influence of various pharmaceutical agents on tear flow as assessed by fluorophotometry.
    Göbbels MJ; Spitznas M
    Adv Exp Med Biol; 1994; 350():385-91. PubMed ID: 8030507
    [No Abstract]   [Full Text] [Related]  

  • 59. Increasing importance of dry eye syndrome and the ideal artificial tear: consensus views from a roundtable discussion.
    Asbell PA
    Curr Med Res Opin; 2006 Nov; 22(11):2149-57. PubMed ID: 17076975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CF101 for dry eye.
    Ashar JN; Mathur A; Sangwan V
    Ophthalmology; 2011 May; 118(5):1011-2; author reply 1012. PubMed ID: 21539995
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.